These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33845362)

  • 1. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
    Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
    ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
    McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
    J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
    Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
    Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
    J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia.
    Phianpiset R; Ruengkhachorn I; Kuljarusnont S; Jareemit N; Udompunturak S
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e495-e506. PubMed ID: 35253996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
    Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
    Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
    McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ
    Br J Cancer; 2010 Mar; 102(5):810-4. PubMed ID: 20160727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
    Deng L; Zhang J; Wu T; Lawrie TA
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
    Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
    Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid.
    Taylor F; Grew T; Everard J; Ellis L; Winter MC; Tidy J; Hancock BW; Coleman RE
    Eur J Cancer; 2013 Oct; 49(15):3184-90. PubMed ID: 23870384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.